Marinomed Biotech Balance Sheet Health
Financial Health criteria checks 1/6
Marinomed Biotech has a total shareholder equity of €-11.8M and total debt of €21.7M, which brings its debt-to-equity ratio to -183.6%. Its total assets and total liabilities are €12.1M and €24.0M respectively.
Key information
-183.6%
Debt to equity ratio
€21.75m
Debt
| Interest coverage ratio | n/a |
| Cash | €1.86m |
| Equity | -€11.84m |
| Total liabilities | €23.99m |
| Total assets | €12.15m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 93Z has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: 93Z has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: 93Z has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: 93Z's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 93Z has sufficient cash runway for 5 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: Insufficient data to determine if 93Z has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.